Heterogeneity of Monoclonal Antibodies(21)

antibodies in solution.J Chromatogr B Analyt Technol Biomed Life Sci818:115–121.

218.Smith MA,Easton M,Everett P,Lewis G,Payne M,Riveros-Moreno V,Allen G.1996.Specific clea-vage of immunoglobulin G by copper ions.Int J Pept Protein Res48:48–55.

219.Allen G,Campbell RO.1996.Specific cleavage of histidine-containing peptides by copper(II).Int J Pept Protein Res48:265–273.

220.Friedman M.1999.Chemistry,biochemistry, nutrition,and microbiology of lysinoalanine, lanthionine,and histidinoalanine in food and other proteins.J Agric Food Chem47:1295–1319. 221.White HB3rd,Merrill AH Jr.1988.Riboflavin-binding proteins.Ann Rev Nutr8:279–299. 222.Farhangi M,Osserman EF.1976.Myeloma with xanthoderma due to an IgG lambdamonoclonal anti-flavin antibody.N Engl J Med294:177–183. 223.Merlini G,Bruening R,Kyle RA,Osserman EF.

1990.The second riboflavin-binding myeloma IgG lambdaDOT.I.Biochemical and functional char-acterization.Mol Immunol27:385–394.

224.Zhu X,Wentworth P Jr,Kyle RA,Lerner RA, Wilson IA.2006.Cofactor-containing antibodies: Crystal structure of the original yellow antibody.

Proc Natl Acad Sci USA103:3581–3585.(Epub 2006Feb3528.)

225.Al-Mashikhi SA,Nakai S.1988.Separation of immunoglobulin and transferrin from blood serum and plasma by metal chelate interaction chroma-tography.J Dairy Sci71:1756–1763.

226.Hale JE,Beidler DE.1994.Purification of huma-nized murine and murine monoclonal antibodies using immobilized metal-affinity chromatogra-phy.Anal Biochem222:29–33.

227.Baker BL,Hultquist DE.1978.A copper-binding immunoglobulin from a myeloma patient.Studies of the copper-binding site.J Biol Chem253:8444–8451.

228.Dower SK,Dwek RA,McLaughlin AC,Mole LE, Press EM,Sunderland CA.1975.The binding of lanthanides to non-immune rabbit immunoglobu-lin G and its fragments.Biochem J149:73–82. 229.Foote J,Milstein C.1994.Conformational isomer-ism and the diversity of antibodies.Proc Natl Acad Sci USA91:10370–10374.

230.James LC,Roversi P,Tawfik DS.2003.Antibody multispecificity mediated by conformational diver-sity.Science299:1362–1367.

231.Sandin S,Ofverstedt LG,Wikstrom AC,Wrange O,Skoglund U.2004.Structure andflexibility of individual immunoglobulin G molecules in solu-tion.Structure12:409–415.

232.Saphire EO,Stanfield RL,Crispin MD,Parren PW,Rudd PM,Dwek RA,Burton DR,Wilson IA.2002.Contrasting IgG structures reveal extreme asymmetry andflexibility.J Mol Biol 319:9–18.233.Minton KW,Karmin P,Hahn GM,Minton AP.

1982.Nonspecific stabilization of stress-suscepti-ble proteins by stress-resistant proteins:A model for the biological role of heat shock proteins.Proc Natl Acad Sci USA79:7107–7111.

234.Kendrick BS,Carpenter JF,Cleland JL,Randolph TW.1998.A transient expansion of the native state precedes aggregation of recombinant human inter-feron-gamma.Proc Natl Acad Sci USA95:14142–14146.

235.Carpenter JF,Kendrick BS,Chang BS,Manning MC,Randolph TW.1999.Inhibition of stress-induced aggregation of protein therapeutics.

Methods Enzymol309:236–255.

236.Wang W,Singh S,Zeng DL,King K,Nema S.2007.

Antibody structure,instability,and formulation.

J Pharm Sci96:1–26.

237.Philo JS.2006.Is any measurement method opti-mal for all aggregate sizes and types?AAPS J 8:E564–E571.

238.Cleland JL,Lam X,Kendrick B,Yang J,Yang TH, Overcashier D,Brooks D,Hsu C,Carpenter JF.

2001.A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody.J Pharm Sci90:310–321. 239.Chen B,Bautista R,Yu K,Zapata GA,Mulkerrin MG,Chamow SM.2003.Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms.

Pharm Res20:1952–1960.

240.Hartmann WK,Saptharishi N,Yang XY,Mitra G, Soman G.2004.Characterization and analysis of thermal denaturation of antibodies by size exclu-sion high-performance liquid chromatography with quadruple detection.Anal Biochem325: 227–239.

241.Breen ED,Curley JG,Overcashier DE,Hsu CC, Shire SJ.2001.Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation.Pharm Res18:1345–1353.

242.Maa YF,Nguyen PA,Andya JD,Dasovich N, Sweeney TD,Shire SJ,Hsu CC.1998.Effect of spray drying and subsequent processing condi-tions on residual moisture content and physical/ biochemical stability of protein inhalation pow-ders.Pharm Res15:768–775.

243.Costantino HR,Andya JD,Nguyen PA,Dasovich N,Sweeney TD,Shire SJ,Hsu CC,Maa YF.1998.

Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharma-ceutical protein,recombinant humanized anti-IgE monoclonal antibody.J Pharm Sci87:1406–1411. 244.Duddu SP,Dal Monte PR.1997.Effect of glass transition temperature on the stability of lyophi-lized formulations containing a chimeric therapeu-tic monoclonal antibody.Pharm Res14:591–595. 245.Andya JD,Hsu CC,Shire SJ.2003.Mechanisms of aggregate formation and carbohydrate excipient

JOURNAL OF PHARMACEUTICAL SCIENCES,VOL.97,NO.7,JULY2008DOI10.1002/jps 2446LIU ET AL.